Detalhe da pesquisa
1.
Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial.
Arthritis Res Ther
; 14(1): R11, 2012 Jan 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-22251436